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Abstract  
There is significant uncertainty over the role of assessment of long-term neurodevelopmental outcome 
(LTO) in neonatal clinical trials. A multidisciplinary working group was established to identify key issues 
in this area and to make recommendations about optimal approaches to evaluate LTO in therapeutic 
trials in newborns, which can be developed by sponsors and investigators with other key stakeholders. A 
key consideration for neonatal trials is the potential for the investigational product to cause widespread 
effects and drives the need to assess outcome in multiple organs. Thus, investigators must assess 
whether the product has an impact on the brain and the potential for it to cause potential effects on 
LTO. Critically, is assessment of LTO an important direct therapeutic target or a safety outcome? Such 
decisions and outcomes need to be specific to the product being studied and use published data, only 
considering expert opinion when prior evidence does not exist. In designing the trial, the balance of 
benefits, costs and burdens of assessments to the researcher and families need to be considered. 
Families and parent advocates should be involved in design and execution of the study. A framework is 
presented for use by all key stakeholders to determine the need, nature, and duration of LTO 
assessments in regulatory trials involving newborn infants. 
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Introduction  
The effect of an investigational medicinal product or other interventions administered to 
newborn infants may be detected well beyond the neonatal period. The extent of the affected 
domains has been set out in a report of a workshop held in 2011.(1) Recent advances in 
neuroprotection following intrapartum hypoxia at term have highlighted the complexity of long 
term neurodevelopmental outcome (LTO) from hypoxic-ischemic encephalopathy.(2,3)  
The study of most pharmacologic and non-pharmacologic interventions in the newborn 
infant will require monitoring of outcomes beyond discharge from inpatient neonatal services. 
This is needed to detect the primary outcome, to confirm persistence of neonatal effects of the 
intervention, or to demonstrate long term safety.(4) Rapid and continued development as well as 
the non-specificity of medicines used in the neonatal period means that  investigational products  
rarely have precisely targeted effects. Products given in the neonatal period may subtly alter the 
developmental trajectory of organ development, for example lung or vascular development (5), 
such that the effects are only detectable as the organ system matures. This phenomenon is 
compounded by the effects of factors other than the study intervention on development and 
maturation as well as a lack of reliable early biomarkers of effectiveness or adverse effects for 
most conditions that appear in children after neonatal illness. 
This narrative review considers factors associated with neonatal long-term 
neurodevelopmental outcomes while drawing attention to other domains when appropriate. It 
reflects the views of a broad spectrum of individuals from clinical practice, industry partners and 
regulators. 
Neonatal long-term outcome studies 
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In general, long-term follow-up is often conducted in studies that are separate yet 
coordinated with the initial clinical trials. Long-term studies are not easy to do as they require 
tracking of children and their families after discharge from hospital for several years or more, 
which can be expensive and overly burdensome.(6)  Trials of investigational products in 
newborn infants may need to include suitable tracking and retention strategies as part of the 
licensing process, unless it can be linked to routine LTO follow up that is part of standard care.  
Dropouts in long term outcome studies are common in both academic and industry based studies 
– and they are rarely at random, preferentially affecting children with adverse outcomes (7,8), 
and those from socially disadvantaged backgrounds.(9,10) Trial size calculations for long term 
studies (e.g. within post-approval registries) need to account for a realistic proportion of dropouts 
in order to ensure adequate data quality.  
Certain effects may not be detectable for many years. For example, lung function tests are 
not reliable until later in childhood (11); executive functions, the building blocks of cognitive 
function in childhood and adult life, differentiate into separable functions that are more reliably 
assessed at school age (12); changes in vascularization affecting blood pressure may not reliably 
be detected until early adolescence(13).  While important outcomes may not manifest until 5-10 
years after exposure, it is not practical to wait this long for licensing / marketing authorization. 
These considerations mean that it is important to determine which LTOs are central to 
licensing and which will inform post-marketing assessments. Direct evidence of clinical benefit 
is usually required for licensing, unless a validated surrogate endpoint can be identified. Many 
assessments currently conducted during the neonatal period are not specific or sensitive 
predictors of important clinical outcomes, either as benefit or harm, and so are unlikely to 
provide validated surrogate endpoints.   
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Delays and difficulties often arise during long-term outcome studies. If long-term studies 
are unnecessarily included in the initial assessment for licensing or marketing authorization, 
there may be delays in approval that prevent infants from accessing a useful product. Delays can 
also lead to reduced feasibility because off-label drug use removes equipoise and because delays 
can cause investigator and parent fatigue.  However, longer-term assessments may be essential to 
establish both safety and efficacy of some investigational products. 
The decision about which outcomes to use as the basis for neonatal licensing should be 
made early during the process to approve the pediatric development plan, or its constituent 
studies. The role and nature of shorter-term outcomes will depend on the natural history of the 
condition, the known and expected properties of the product, and the specific neonatal 
population that is investigated. The licensed indication may not be the same as the clinical 
diagnosis. Outcomes need to be relevant to families and clinicians (and other stakeholders such 
as reimbursement agencies). The sponsor should present a well-reasoned proposal for which 
outcomes should contribute to licensing with a specific focus on outcomes that should be 
included in Pharmacovigilance Risk Management Plans or adaptive licensing.  Short-term risks 
and benefits may not be concordant with long-term outcomes. For example, cranial ultrasound 
may not detect abnormalities in infants who subsequently develop cerebral palsy, neurocognitive 
or behavioral problems. However, potential discordance is a justification for well-designed 
surveillance that makes account of this possibility, not for delaying licensing once evidence of a 
useful clinical effect is apparent. A transient benefit seen over 1 – 2 years that is not reflected in 
later life may still be valued by families and payers. 
Understanding the multiple influences that are active during childhood is equally 
important, as these may confound the results of clinical trials.  For example, males have worse 
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outcomes than females in many neonatal studies. Family structure may influence how a child 
acquires skills, as may the language spoken at home (if more than one), particularly when testing 
is done as structured language is appearing in the second and third years of life. Finally, the 
socio-economic status of the family and availability of interventional services may modify both 
short and long-term outcomes.  Data collection should capture these influences as it is necessary 
to include sensitivity analyses as secondary exploratory analyses. In large multicenter, 
randomized, controlled trials, sample size and randomization should be robust enough to ensure 
even allocation of confounders between study groups. However, randomization does not 
necessarily influence the balance of confounders that may arise subsequently (e.g. meningitis 
occurring in infancy or new onset of seizure disorders; both may affect neurodevelopment).  
Framework for planning LTO evaluations 
This section presents general points to be considered when assessing the need for, and 
structure of, LTO evaluations for neonatal trials. Points to consider may include: 
1. Justify all trial design components according to the specific trial drug – This will include the 
investigational product itself, the indication for use of the product, and the population where 
it will be tested.  Other interventions, such as the use of therapeutic hypothermia during 
hypoxic ischemic encephalopathy, should be reflected in the justification. All components 
should be justified using data, reverting to expert professional opinion only when necessary.  
2. Account for the nature of the outcome as a primary target or safety consideration – where 
the outcome is a direct consequence of the intervention, a formal evaluation of a defined 
LTO is necessary, tailored to detect the proposed effect (Figure 1, Panel A). Where the 
investigational product may be associated with adverse LTO, this may not necessarily be a 
direct consequence of the treatment effect, but other causal pathways. In this instance, it is 
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safer to evaluate all outcome domains (Figure 1, Panel B).  There is a co-dependency of 
adverse outcome domains primarily because many causal pathways are common. The 
pathogenesis of poor neurodevelopmental outcomes is complex and many pre- and postnatal 
influences combine with the child’s environment to produce a particular outcome.  These 
influences will usually be evenly segregated between trial groups through the randomization 
process. In some trials, it may be appropriate to ensure even recruitment through 
stratification or minimization techniques to account for the confounding influences that are 
identifiable at study entry.  Examples of important confounders for LTO are male sex, 
gestational age, fetal growth, neonatal brain injury, and socioeconomic status (14-16). Trial 
data should include all of these potential confounders. 
3. Balance the benefits, costs, and burden of the assessments – these may be balanced against 
the assessments themselves, the intervention, the indication, and the population (including 
co-morbidities). 
With respect to each time that contact is made with a family, it is important to consider: 
a. The burden on the participant and family 
b. The burden on the health care system both during the trial and subsequently if the role 
of the intervention changes after the trial (i.e. use becomes more generalized) 
c. Costs to the family (direct and indirect) against utility for the sponsor 
With respect to the intervention, consider: 
d. Benefits against risk  
i. Anticipated 
ii. Potentially unanticipated 
iii. The magnitude of the benefit or risk 
©    2019 Macmillan Publishers Limited, part of Springer Nature.
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With respect to the population, consider: 
e. What are the inherent risks in the population (the impact of the initial disease process 
on LTO) that the investigational product seeks to mitigate? 
The direct costs and resources required for long term follow-up should be identified and 
guaranteed before the trial starts. Sponsors, clinicians, academics and relevant advocacy 
groups should all facilitate long-term follow-up by designing the studies carefully and by 
contributing to /advertising the studies when appropriate. Health care systems should provide 
support to long-term follow-up studies by providing suitable infrastructure that promotes 
long-term follow up – which in any case is essential for the responsible clinical care of 
newborn infants (especially preterm infants) and by maintaining systems that provide unique 
identifiers. The collection of high quality data in routine clinical practice may also contribute 
to LTO assessments but requires standardization and coordination across multiple settings 
that may not be feasible.  
4. Involve families and parent advocates in the study design – this should be proportional to the 
design and involvement of the trial and likely benefit. As a general principle, the input of 
families will assist in ensuring that the trial is relevant, acceptable and feasible to service 
users.  It is acknowledged that sometimes such input may lead to alteration of commonly 
used assessments; e.g. specific parental questions or instruments. For example, parents may 
request that certain questions be removed from standard questionnaires because they appear 
to be insensitive in current usage, which may change the overall psychometric properties of 
the instrument. However, the input of families is often of great benefit in ensuring that the 
risk/benefits/burden of the trial are optimized. Where such input is sought, resources need to 
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be made available to participants to facilitate their input, including reimbursement for their 
time and travel. 
5. Account for the nature of the intervention – in terms of likely effects and use: 
a) What is known about drug disposition in the target group (absorption, 
distribution, metabolism, excretion, toxicity, integrity of the blood brain barrier)? 
b) What is known of toxicology in appropriate pre-clinical models? 
c) Are there likely effects from excipients or formulation strategies? 
d) How is the drug to be administered? 
e) What is known about the neurological impact in terms of benefits or harms, the 
likelihood of these impacts, and the extent to which these can be excluded as 
issues? 
6. Account for the background morbidity in the population – medicines rarely remove all 
morbidity in clinical populations as most morbidities have complex and multifactorial 
etiologies.  In any population, there will be background morbidities which may confound the 
effects that are being studied. Thus, particularly when attempting to evaluate the effects of 
drugs on LTO, the population baseline outcomes must be known and will differ – some 
examples of populations with very differing risks may be: 
a. Term infants with suspected infection 
b. Term infants recruited to vaccine studies  
c. Term infants with hypoxic-ischemic encephalopathy (HIE) 
d. Preterm infants ≤32 weeks PMA with an oxygen requirement 
e. Preterm infants ≤26 weeks with poor perfusion and/or hypotension 
©    2019 Macmillan Publishers Limited, part of Springer Nature.
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7. Account for the nature of the trial – several types of investigation are relevant to these 
considerations, including regulated submission for marketing authorization / labeling, 
contribution to prescribing (strategic trials), and to health technology assessment. Data from 
trials may be relevant to other trial situations and data should be re-used for other relevant 
purposes if at all possible, to minimize the ‘ask’ of families. Furthermore, the studies and 
data required to obtain marketing authorization may not be suitable to change clinical 
practice or justify reimbursement, and the sponsor may feel it is necessary to add assessments 
beyond these minimal requirements. However, each additional assessment must be 
thoroughly justified. 
8. The plan for LTO evaluation – Following consideration of the above issues, a bespoke plan 
can be made or one or more of the following plans may be followed: 
a. No specific long term follow up is necessary beyond the initial hospital discharge 
b. Studies should retain a unique identifier to allow record linkage with routine health 
data 
c. Studies should retain contact with the family and ask general questions about their 
health status 
d. Studies should screen participants for important LTO: assessments should be 
established a priori and any positive screens evaluated if/when they occur 
e. There should be formal follow-up of all participants at appropriate time intervals to 
directly evaluate their clinical and neurodevelopmental status.  
f. Follow-up should be conducted using a registry (new or existing) that includes 
participants in studies recruiting during pregnancy or the neonatal period. This could 
include other infants exposed to the IMP. 
©    2019 Macmillan Publishers Limited, part of Springer Nature.
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The plan will be different depending on the feasibility of ongoing surveillance, the relative 
prevalence of anticipated outcomes in different populations, and on the likelihood of brain or 
other organs having adverse outcomes.  
Technical Issues in planning evaluation of long-term neurodevelopmental outcomes 
The on-line Supplemental Material describes the considerations and details of specific 
neurodevelopmental assessments, drawn from professional consensus and previous studies, with 
explanatory notes on the reasons for choice of measure, and categorization of outcomes for 
safety purposes. These categories are used worldwide as outcomes for a range of clinical and 
medicine-related studies and are especially relevant in neonatal trials. If an investigational 
product is to achieve clinical acceptability, the quality and nature of the outcome assessment 
should be understood by the entire clinical community with reference to common practice. That 
is not to say that innovative outcomes are not of value, but that they must be set in context and be 
of sufficient validity, reliability, and quality to have confidence in clinical applicability. Further, 
specific products may need tailored outcomes depending on the target and the nature of the organ 
effect that is being studied. 
With respect to neurodevelopmental outcomes, trials may be grouped as those where the 
investigational product is targeting specific neurological outcomes, or where general safety 
monitoring is required which could include neurodevelopmental outcome.  Although specific 
recommendations of assessment methods are made (in an attempt to standardize and harmonize 
approaches), these examples are not intended to preclude the use of other instruments or 
assessment tools.  
Ages at assessment   
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Because of the lack of robust biomarkers for long term neurodevelopmental outcomes, 
which are needed, it is necessary to evaluate trial participants up to an age at which the 
evaluation identifies reliable indicators of long-term outcomes.  For efficacy of neurologically 
focused interventions or for assessment of neurological safety, the primary outcome should be 
evaluated at 2 years of age (corrected for prematurity if appropriate), as the focus of the first 
phase of LTO monitoring.  Such an assessment is performed by many neonatal teams for audit 
and quality control purposes in high-risk cohorts and may be adapted during data collection for 
trials. The rationale and recommended classifications have been published (Figure 3) and the 
assessments are discussed in greater detail in the web supplement. These should be supplemented 
with treatment-specific outcomes as appropriate (e.g. seizure frequency in the study of an anti-
epileptic medication). These outcomes may be considered necessary to support licensing where 
the effects of the investigational product are not directly quantifiable during the neonatal period. 
To rely completely on 2 year (or even earlier) outcomes runs the risk of misclassification 
of final outcome and of missing more subtle cognitive, behavioral, or sensorimotor outcomes.  
Assessments performed at 2 years corrected gestational age are performed when many 
pathological outcomes are still differentiating as part of normal child development. Accurate 
ascertainment of neurocognitive, academic, and behavioral assessments requires children to be 
followed until later in childhood when school performance can be better assessed. All of these 
conditions are more accurately measured at later ages and tend to differentiate during the first 4 – 
6 years after birth. From early school age, cognitive scores tend to track in individuals and more 
precise definition of motor and sensory outcomes is possible. Where appropriate, these 
assessments should be combined with treatment-specific measures to enhance the understanding 
of the very long-term effects of the product.  While outcomes at 5 – 6 years of age are important 
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confirmatory assessments, generally they should supplement licensing processes and are not 
necessarily required for initial licensing because of the lag time to their detection. 
In some settings, it may be prudent to collect routine data from national systems to 
support safety and very long-term outcomes – examples of this may be ongoing mortality or 
cancer registration monitoring, or the results of standardized national educational attainment 
tests.  As most studies are carried out in international settings, care needs to be taken when 
proposing to use such assessments as these may not be an adequate substitute for research-
specific assessments, and highlights difficulties in comparing outcomes between different 
healthcare and education systems. This may be due to inconsistencies in granularity or data 
quality, or in the scope of geographic coverage relative to trial recruitment. Nevertheless, these 
are potentially important surveillance tools and may identify important long-term risks when 
appropriate. In addition to these assessments it may be prudent to add additional focused 
assessment to support licensing of particular products. All ongoing data collection should meet 
relevant national data protection regulations, which should be factored into trial planning and 
delivery. 
Post-discharge deaths 
At each assessment point, the number of patients who have died and the principal reason 
for death should be recorded, together with any pre-existing identified disabilities.  Deaths may 
confound some trials and any assessment plans should indicate how deaths are to be treated in 
the analysis, even if the product is not thought to directly relate to the death. Since death is often 
a competing outcome, it is not uncommon to see combined primary outcome measures which 
include death or another serious morbidity. 
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Conclusion 
Clinical trials of investigational medicinal products in the neonatal period may require 
long-term evaluations, for assessment of both therapeutic and safety signals. Drugs may have 
negative effects on the infant, both directly and unanticipated, which may be detected early in the 
neonatal period or later at school age.  This paper conceptualizes recommendations for the 
examination of long term outcomes and proposes a framework within which more specific 
outcomes pertinent to the investigational product may be added. 
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Legends for Figures: 
Figure 1:  Causal pathways to adverse long term outcomes and needs for assessment. Panel A: 
where the outcome is a direct consequence of the intervention, a formal evaluation of a 
defined LTO is necessary, tailored to detect the proposed effect.  
Panel B: where the outcome is an indirect consequence of the intervention it is safer to 
evaluate all domains of relevant LTOs. 
Figure 2: Surveillance of Cerebral Palsy in Europe (SCPE) classification of sub-types of 
Cerebral Palsy. 
Figure 3: Example of a consensus scheme for categorization of health status at 2 years of age, 
including neurodevelopmental outcomes.(17) 
Figure 4: Summary of proposals for long term neurodevelopmental outcome assessment 
strategy. 
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Summary of proposals for long term neurodevelopmental outcome assessment 
strategy. 
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